Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A

Novel-antibiotics are urgently needed to combat an increase in morbidity and mortality due to resistant bacteria. The preclinical candidate corallopyronin A (CorA) is a potent antibiotic against Gram-positive and some Gram-negative pathogens for which a solid oral formulation was needed for further preclinical testing of the active pharmaceutical ingredient (API). The neat API CorA is poorly water-soluble and instable at room temperature, both crucial characteristics to be addressed and overcome for use as an oral antibiotic. Therefore, amorphous solid dispersion (ASD) was chosen as formulation principle. The formulations were prepared by spray-drying, comprising the water-soluble polymers povidone and copovidone. Stability (high-performance liquid chromatography, Fourier-transform-infrared spectroscopy, differential scanning calorimetry), dissolution (biphasic dissolution), and solubility (biphasic dissolution, Pion’s T3 apparatus) properties were analyzed. Pharmacokinetic evaluations after intravenous and oral administration were conducted in BALB/c mice. The results demonstrated that the ASD formulation principle is a suitable stability- and solubility-enhancing oral formulation strategy for the API CorA to be used in preclinical and clinical trials and as a potential market product.

Download the full article here: Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A

or continue reading here: Krome, A.K.; Becker, T.; Kehraus, S.; Schiefer, A.; Steinebach, C.; Aden, T.; Frohberger, S.J.; López Mármol, Á.; Kapote, D.; Jansen, R.; Chaverra-Muñoz, L.; Hübner, M.P.; Pfarr, K.; Hesterkamp, T.; Stadler, M.; Gütschow, M.; König, G.M.; Hoerauf, A.; Wagner, K.G. Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A. Pharmaceutics 2020, 12, 1105.

Keywords and Materials: Corallopyronin A (CorA); antibiotic; anthelmintic; povidone (PVP); copovidone (PVP/VA); solubility enhanced formulation; stability enhanced formulation; spray-dried amorphous solid dispersion (ASD); biphasic dissolution (BiPHa+); pharmacokinetic analysis, Polyvinylpyrrolidone (Kollidon® 30 LP) , vinylpyrrolidone-vinyl acetate copolymer (VIVAPHARM® PVP/VA 64) Ethanol 99.8%, Kolliphor® HS 15.